Cargando…

Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient

Monoclonal antibodies (mAbs) directed against the spike of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are effective therapeutic options to combat infections in high-risk patients. Here, we report the adaptation of SARS-CoV-2 to the mAb cocktail REGN-COV in a kidney transplant patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaki, Lena, Weigang, Sebastian, Kern, Lisa, Kramme, Stefanie, Wrobel, Antoni G., Grawitz, Andrea B., Nawrath, Philipp, Martin, Stephen R., Dähne, Theo, Beer, Julius, Disch, Miriam, Kolb, Philipp, Gutbrod, Lisa, Reuter, Sandra, Warnatz, Klaus, Schwemmle, Martin, Gamblin, Steven J., Neumann-Haefelin, Elke, Schnepf, Daniel, Welte, Thomas, Kochs, Georg, Huzly, Daniela, Panning, Marcus, Fuchs, Jonas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085998/
https://www.ncbi.nlm.nih.gov/pubmed/37037847
http://dx.doi.org/10.1038/s41467-023-37591-w
_version_ 1785022049570258944
author Jaki, Lena
Weigang, Sebastian
Kern, Lisa
Kramme, Stefanie
Wrobel, Antoni G.
Grawitz, Andrea B.
Nawrath, Philipp
Martin, Stephen R.
Dähne, Theo
Beer, Julius
Disch, Miriam
Kolb, Philipp
Gutbrod, Lisa
Reuter, Sandra
Warnatz, Klaus
Schwemmle, Martin
Gamblin, Steven J.
Neumann-Haefelin, Elke
Schnepf, Daniel
Welte, Thomas
Kochs, Georg
Huzly, Daniela
Panning, Marcus
Fuchs, Jonas
author_facet Jaki, Lena
Weigang, Sebastian
Kern, Lisa
Kramme, Stefanie
Wrobel, Antoni G.
Grawitz, Andrea B.
Nawrath, Philipp
Martin, Stephen R.
Dähne, Theo
Beer, Julius
Disch, Miriam
Kolb, Philipp
Gutbrod, Lisa
Reuter, Sandra
Warnatz, Klaus
Schwemmle, Martin
Gamblin, Steven J.
Neumann-Haefelin, Elke
Schnepf, Daniel
Welte, Thomas
Kochs, Georg
Huzly, Daniela
Panning, Marcus
Fuchs, Jonas
author_sort Jaki, Lena
collection PubMed
description Monoclonal antibodies (mAbs) directed against the spike of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are effective therapeutic options to combat infections in high-risk patients. Here, we report the adaptation of SARS-CoV-2 to the mAb cocktail REGN-COV in a kidney transplant patient with hypogammaglobulinemia. Following mAb treatment, the patient did not clear the infection. During viral persistence, SARS-CoV-2 acquired three novel spike mutations. Neutralization and mouse protection analyses demonstrate a complete viral escape from REGN-COV at the expense of ACE-2 binding. Final clearance of the virus occurred upon reduction of the immunosuppressive regimen and total IgG substitution. Serology suggests that the development of highly neutralizing IgM rather than IgG substitution aids clearance. Our findings emphasise that selection pressure by mAbs on SARS-CoV-2 can lead to development of escape variants in immunocompromised patients. Thus, modification of immunosuppressive therapy, if possible, might be preferable to control and clearance of the viral infection.
format Online
Article
Text
id pubmed-10085998
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-100859982023-04-12 Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient Jaki, Lena Weigang, Sebastian Kern, Lisa Kramme, Stefanie Wrobel, Antoni G. Grawitz, Andrea B. Nawrath, Philipp Martin, Stephen R. Dähne, Theo Beer, Julius Disch, Miriam Kolb, Philipp Gutbrod, Lisa Reuter, Sandra Warnatz, Klaus Schwemmle, Martin Gamblin, Steven J. Neumann-Haefelin, Elke Schnepf, Daniel Welte, Thomas Kochs, Georg Huzly, Daniela Panning, Marcus Fuchs, Jonas Nat Commun Article Monoclonal antibodies (mAbs) directed against the spike of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are effective therapeutic options to combat infections in high-risk patients. Here, we report the adaptation of SARS-CoV-2 to the mAb cocktail REGN-COV in a kidney transplant patient with hypogammaglobulinemia. Following mAb treatment, the patient did not clear the infection. During viral persistence, SARS-CoV-2 acquired three novel spike mutations. Neutralization and mouse protection analyses demonstrate a complete viral escape from REGN-COV at the expense of ACE-2 binding. Final clearance of the virus occurred upon reduction of the immunosuppressive regimen and total IgG substitution. Serology suggests that the development of highly neutralizing IgM rather than IgG substitution aids clearance. Our findings emphasise that selection pressure by mAbs on SARS-CoV-2 can lead to development of escape variants in immunocompromised patients. Thus, modification of immunosuppressive therapy, if possible, might be preferable to control and clearance of the viral infection. Nature Publishing Group UK 2023-04-10 /pmc/articles/PMC10085998/ /pubmed/37037847 http://dx.doi.org/10.1038/s41467-023-37591-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Jaki, Lena
Weigang, Sebastian
Kern, Lisa
Kramme, Stefanie
Wrobel, Antoni G.
Grawitz, Andrea B.
Nawrath, Philipp
Martin, Stephen R.
Dähne, Theo
Beer, Julius
Disch, Miriam
Kolb, Philipp
Gutbrod, Lisa
Reuter, Sandra
Warnatz, Klaus
Schwemmle, Martin
Gamblin, Steven J.
Neumann-Haefelin, Elke
Schnepf, Daniel
Welte, Thomas
Kochs, Georg
Huzly, Daniela
Panning, Marcus
Fuchs, Jonas
Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient
title Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient
title_full Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient
title_fullStr Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient
title_full_unstemmed Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient
title_short Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient
title_sort total escape of sars-cov-2 from dual monoclonal antibody therapy in an immunocompromised patient
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10085998/
https://www.ncbi.nlm.nih.gov/pubmed/37037847
http://dx.doi.org/10.1038/s41467-023-37591-w
work_keys_str_mv AT jakilena totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT weigangsebastian totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT kernlisa totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT krammestefanie totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT wrobelantonig totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT grawitzandreab totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT nawrathphilipp totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT martinstephenr totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT dahnetheo totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT beerjulius totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT dischmiriam totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT kolbphilipp totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT gutbrodlisa totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT reutersandra totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT warnatzklaus totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT schwemmlemartin totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT gamblinstevenj totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT neumannhaefelinelke totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT schnepfdaniel totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT weltethomas totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT kochsgeorg totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT huzlydaniela totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT panningmarcus totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient
AT fuchsjonas totalescapeofsarscov2fromdualmonoclonalantibodytherapyinanimmunocompromisedpatient